Ingenol disoxate

Drug Profile

Ingenol disoxate

Alternative Names: LEO-43204

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator LEO Pharma
  • Class Antiacnes; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Actinic keratosis
  • Phase II Acne vulgaris

Most Recent Events

  • 19 Apr 2017 LEO Pharma plans a phase III trial for Actinic keratosis and Squamous cell cancer (Second-line therapy or greater, In children, In adolescents, In adults, In elderly) in USA (NCT03115476)
  • 01 Apr 2017 LEO Pharma completes a phase II trial in Acne vulgaris in USA (Topical) (NCT02575950)
  • 23 Aug 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top